The University of Sydney logo
Request Access

SAVE SIGHT REGISTRIES PROJECT

Fight Retinal Blindness

Fight Retinal Blindness (FRB!) collects high quality outcomes data from patients in the clinical setting, tracking the effectiveness and safety of new and emerging treatments for age related macular degeneration, diabetic macular oedema, other causes of macular neovascularisation and retinal vein occlusion, among the commonest causes of vision impairment and blindness worldwide.

Hear from our Chief Investigator

Professor Mark Gillies on how Fight Retinal Blindness is improving treatment outcomes.

OVERVIEW

About the project

FRB! was the first Save Sight Registries project, and other modules have grown from it. It is a web based platform for tracking the long term effectiveness and safety of treatments for retinal, mostly macular, diseases.

It brings together four registries of treatment outcomes: age related macular degeneration (wet and dry), diabetic macular oedema, other causes of macular neovascularisation and retinal vein occlusion. Its dataset helps determine the right timing and choice of treatment for patients with macular disease.

What participation involves

Take part in national and international audits, contribute data and co author publications
Export your own data for your own audits
Anonymously benchmark your patient outcomes against those of your colleagues
Collect patient reported quality of life questionnaires, completed on a tablet or phone

FRB! REGISTRIES

The registries

The FRB! project is made up of four registries, each tracking real world treatment outcomes for a different retinal condition. You can take part in as many registries as you like.

AMD

Age related macular degeneration

The first module of the FRB! project, mainly tracking outcomes of eye injections for wet (neovascular) AMD. Since 2023 it also tracks outcomes of new treatments for advanced dry, or atrophic, AMD.

DME

Diabetic macular oedema

Tracks treatment outcomes for DME, the most common cause of vision loss in people with diabetes, with a focus on whether new treatments perform as well as expected.

For example, the data showed that aflibercept had a stronger effect on DME and RVO after its general release in 2013.

MNV

Other Causes of Macular Neovascularisation

Tracks treatment outcomes for macular neovascularisation (MNV) from causes other than age related macular degeneration, such as pathological myopia and inflammatory conditions. These less common forms of MNV often affect younger patients and have far less published real world evidence.

RVO

Retinal vein occlusion

The only international registry designed specifically to track the outcomes of RVO, the second commonest vascular disease of the retina after diabetic macular oedema.

INVESTIGATORS

Leading Fight Retinal Blindness

Professor Mark Gillies

CHIEF INVESTIGATOR AND INNOVATOR

Professor Mark Gillies

MB BS, PhD, FRANZCO

Director of Research, Save Sight Institute, Dept. of Ophthalmology and Eye Health, University of Sydney

Professor Daniel Barthelmes

CO INVESTIGATOR AND INNOVATOR

Professor Daniel Barthelmes

MD, PhD, EMBA, FEBO, FMH

Director, Department of Ophthalmology, University Hospital Zurich and University of Zurich

Meet the full leadership team →